Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Depreciation & Amortization (CF): 2015-2020

Historic Depreciation & Amortization (CF) for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to $80,149.

  • Outlook Therapeutics' Depreciation & Amortization (CF) fell 90.98% to $80,149 in Q3 2020 from the same period last year, while for Sep 2020 it was $554,069, marking a year-over-year decrease of 83.52%. This contributed to the annual value of $113,859 for FY2024, which is 157.67% up from last year.
  • According to the latest figures from Q3 2020, Outlook Therapeutics' Depreciation & Amortization (CF) is $80,149, which was down 34.46% from $122,297 recorded in Q2 2020.
  • Over the past 5 years, Outlook Therapeutics' Depreciation & Amortization (CF) peaked at $888,868 during Q3 2019, and registered a low of $80,149 during Q3 2020.
  • In the last 3 years, Outlook Therapeutics' Depreciation & Amortization (CF) had a median value of $816,541 in 2019 and averaged $572,152.
  • In the last 5 years, Outlook Therapeutics' Depreciation & Amortization (CF) surged by 42.14% in 2016 and then tumbled by 90.98% in 2020.
  • Outlook Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $669,780 in 2016, then grew by 1.02% to $676,624 in 2017, then increased by 21.64% to $823,077 in 2018, then plummeted by 78.70% to $175,341 in 2019, then plummeted by 90.98% to $80,149 in 2020.
  • Its Depreciation & Amortization (CF) was $80,149 in Q3 2020, compared to $122,297 in Q2 2020 and $176,282 in Q1 2020.